Drug Search Results
More Filters [+]

ABBV-RGX-314

Alternative Names: ABBV-RGX-314, ABBVRGX314, rgx-314, rgx314, rgx 314
Latest Update: 2024-10-30
Latest Update Note: News Article

Product Description

ABBV-RGX-314 is our product candidate for the treatment of wet age-related macular degeneration (AMD). ABBV-RGX-314 is being developed as a novel, one-time treatment for wet AMD that includes the NAV® AAV8 vector containing a gene encoding for a monoclonal anti-VEGF antibody fragment. (Sourced from: https://www.regenxbio.com/therapeutic-programs/)

Mechanisms of Action: Gene Therapy,VEGF

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: Regenxbio

Clinical Description

Map of Global Clinical Trials for ABBV-RGX-314

Countries in Clinic: Canada, France, Germany, Hungary, Italy, Japan, Puerto Rico, Spain, United Kingdom, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Neovascular age-related macular degeneration|Wet Macular Degeneration

Phase 2: Choroid Diseases|Diabetic Retinopathy|Macular Edema

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RGX-314 SRLTFU

P2

Enrolling by invitation

Neovascular age-related macular degeneration|Wet Macular Degeneration

2028-12-01

24%

RGX-314-3101/M23-409

P3

Unknown Status

Neovascular age-related macular degeneration

2026-11-30

ASCENT

P3

Recruiting

Neovascular age-related macular degeneration|Wet Macular Degeneration

2025-11-01

AAVIATE

P2

Recruiting

Wet Macular Degeneration|Neovascular age-related macular degeneration

2025-10-21

Recent News Events